

**Anti-NGAL (dog)**  
**Mouse monoclonal antibody**

Subclass: IgG2a/k

CAT. NO.

**ABS 047-17**

Clone: 17

---

SPECIFICITY	ABS 047-17 binds dog NGAL (neutrophil gelatinase-associated lipocalin )
IMMUNOGEN	Recombinant dog NGAL
TESTED APPLICATIONS	ELISA, WB, IHC-P
SPECIES REACTIVITY (POSITIVE)	Dog
SPECIES REACTIVITY (NEGATIVE)	Human, mouse, rat
EPITOPE SPECIFICITY	Not determined

---

**PRESENTATION**

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

---

**APPLICATION**

**ELISA:** ABS 047-17 binds free dog NGAL.  
ABS 047-17 (as capture antibody) forms a sandwich ELISA pair with ABS 047-14 (as biotinylated detection antibody) for measuring dog NGAL, giving a detection limit of 5 pg/mL in an unoptimized buffer assay.

**WB:** ABS 047-17 can be used in Western blotting.

**IHC:** ABS 047-17 works in IHC on formalin-fixed, paraffin-embedded sections.

**TARGET**

Dog neutrophil gelatinase-associated lipocalin (NGAL; also called lipocalin 2 or siderocalin) may, by analogy with its homologues in other mammalian species, be released from activated neutrophils in inflammation or infection, from certain epithelial cancers, and more dramatically from renal tubular cells in response to ischemic or nephrotoxic injury.

**REFERENCES****CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.